Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on

AIDS. 2006 Jan 9;20(2):289-91. doi: 10.1097/01.aids.0000202651.41397.db.

Abstract

Progression to AIDS and death for 1129 HIV seroconverters from the GEMES cohort were analysed by calendar period (1996-1997, 1998-1999, 2000 onwards). A further hazard reduction was observed for a later period for both. Intravenous drug users (IDU) had a faster progression. The results highlighted the importance of monitoring the effectiveness of highly active antiretroviral therapy and to improve public health strategies directed to IDU to reduce inequity in HIV infection care.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / mortality
  • Acquired Immunodeficiency Syndrome / prevention & control*
  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Disease Progression
  • Epidemiologic Methods
  • Female
  • HIV Seropositivity / drug therapy*
  • HIV Seropositivity / epidemiology
  • Humans
  • Male
  • Spain / epidemiology
  • Substance Abuse, Intravenous / complications
  • Treatment Outcome